SciFluor - Biotech
.
Leveraging Fluorine Chemistry to Develop Potent, Selective, and Optimized Treatments for Unmet Medical Needs
SciFluor pioneers the design and development of advanced small molecule therapeutic candidates targeting critical pathways in retinal diseases, fibrosis, and neurological disorders. Our proprietary fluorine-based medicinal chemistry enhances potency, selectivity, and pharmacokinetic profiles, aiming to deliver next-generation treatments.
.
Company Overview
SciFluor specializes in cutting-edge small molecule therapeutics designed using strategic fluorine incorporation. Our lead candidate SF0166 targets retinal diseases such as Diabetic Macular Edema (DME) and wet Age-related Macular Degeneration (wet-AMD) via topical eye drop formulation. Beyond ophthalmology, our expanding pipeline focuses on fibrosis and neurology.
Our Approach
Fluorine-Driven Design : Enhancing dr ug-like properties
Targeted Therapeutics : Focus on integrin antagonists and novel pathways
Clinical Development : Rigorous Phase I/II trials with promising results
Patent Protection : Robust intellectual property portfolio
Lead Therapeutic Candidate SF0166 for Retinal Diseases :
Diabetic Macular Edema (DME) and Wet Age-Related Macular Degeneration (wet-AMD)
Fluorine-Driven Compound Design : Enhancing Potency and Pharmacokinetics
The company strategically incorporates fluorine atoms into small molecules to optimize therapeutic candidates for superior potency, high selectivity, and favorable pharmacokinetic characteristics. This approach supports the development of best-in-class compounds aimed at improving treatment outcomes.
Expanding Pipeline: Early-Stage Programs in Fibrosis and Neurology
Beyond ophthalmology, SciFluor actively advances early-stage research programs focusing on fibrosis and neurological disorders. These projects apply the company’s expertise in fluorine chemistry and small molecule design to innovate novel therapeutic options.
Strong Intellectual Property Portfolio and Industry Backing
SciFluor maintains a broad and growing patent portfolio covering its therapeutic candidates and their applications, reinforcing its position in the pharmaceutical development landscape. The company operates as a subsidiary of Allied Minds plc (ALM.L), a Boston-based firm specializing in intellectual property commercialization and early-stage technology and life science ventures.